IDEAYA Biosciences (IDYA) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Pipeline and regulatory progress

• Final NDA submission for darovasertib in first-line metastatic uveal melanoma is imminent, with all modules nearly complete and positive pre-NDA discussions with the FDA, including potential for an all-comers label.

• Phase III adjuvant study for darovasertib has begun enrollment, while neoadjuvant trial faces delays due to strict eligibility criteria; decision on compendium listing or further trials expected by year-end.

• Data from HLA-A2 positive patients will be presented at ESMO, including response rate, PFS, and OS, with compendium listing to be pursued post-approval.

• Pre-launch activities include building a sales force of 25–30 reps, aiming for launch readiness in early next year, with pricing strategy and payer discussions underway.

Clinical development and strategy

• DLL3 TOP1 ADC (IDE849) program is advancing in small cell lung cancer and neuroendocrine carcinoma, with phase III design finalized after FDA Type C meeting and focus on post-IMDELLTRA population.

• ESMO will feature mature efficacy data in 100 patients, including landmark 12-month OS, with expectations for high response rates and PFS of 6–7 months.

• Dose alignment with FDA achieved (2.4 or 3.5 mg/kg), with most patients in ongoing studies being post-IMDELLTRA and showing responses.

• Frontline strategy may include novel combinations, such as PARP inhibitors, with data-driven approach guiding future studies.

• Accelerated approval for phase III trial could be supported by interim response rate and DOR, with rapid enrollment anticipated.

Market and competitive landscape

• DLL3 TOP1 ADC class shows better safety and efficacy profiles compared to other modalities, expected to become an anchor therapy in small cell lung cancer.

• Market share will depend on data quality, with parallels drawn to HER2 targeting in breast cancer.

• Neuroendocrine carcinoma represents a significant opportunity due to high unmet need and limited standard of care.